NDLI: Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Please wait, while we are loading the content...

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Strengthening information systems for heart health in Canada.

Mind the gap: Opportunities for improving end-of-life care for patients with advanced heart failure.

Evaluation of coronary atheroma by 64-slice multidetector computed tomography: Comparison with intravascular ultrasound and angiography.

Coronary artery bypass graft surgery and primary percutaneous coronary intervention choices in patients with similar coronary anatomy: A computer-based simulation examines the sex gap.

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.

Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification.

Community support of patients with a left ventricular assist device: The Toronto General Hospital experience.

Thrombolysis versus primary percutaneous coronary intervention for ST elevation myocardial infarctions at Chilliwack General Hospital.

Treatment delay in ST elevation myocardial infarction care in a community hospital -- a cautionary tale.

Creating synergy in our health system: The challenges of primary angioplasty.

Left ventricular pseudoaneurysm: The role of multimodality cardiac imaging.

Left ventricular thrombus.

A multifaceted approach to intracoronary thrombus: Use of pharmacology, an aspiration catheter and an embolic protection device.

Year: 2009 Volume: 25 Issue: 10

Year: 2009 Volume: 25 Issue: 9

Year: 2009 Volume: 25 Issue: 8

Year: 2009 Volume: 25 Issue: 7

Year: 2009 Volume: 25 Issue: 6

Year: 2009 Volume: 25 Issue: 5

Year: 2009 Volume: 25 Issue: 4

Year: 2009 Volume: 25 Issue: 3

Year: 2009 Volume: 25 Issue: 2

Year: 2009 Volume: 25 Issue: 1

Year: 2009 Volume: 25 Issue: Supplementary A

Year: 2008 Volume: 24

Year: 2007 Volume: 23

Year: 2006 Volume: 22

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Warren, A. E. Hamilton, R. M. Bélanger, S. A. Gray, C. Gow, R. M. Sanatani, S. Côté, J-M Lougheed, J. LeBlanc, J. Martin, S. Miles, B. Mitchell, C. Gorman, D. A. Weiss, M. Schachar, R.
Spatial Coverage	Canada
Description	Author Affiliation: Warren AE ( IWK Health Centre, Dalhousie University, Halifax, Nova Scotia. andrew.warren@iwk.iwk.nshealth.ca)
Abstract	Regulatory decisions and scientific statements regarding the management of attention-deficit hyperactivity disorder (ADHD) raise questions about the safety of medications and the appropriate pretreatment evaluation to determine suitability for treatment with medication. This is particularly true in the setting of known structural or functional heart disease. The present paper reviews the available data, including peer-reviewed literature, data from the United States Food and Drug Administration Web site on reported adverse reactions in children using stimulant medication, and Health Canada data on the same problem. A consensus-based guideline on appropriate assessment is provided, based on input from members of the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry, with specific expertise and knowledge in the areas of both ADHD and pediatric cardiology. The present statement advocates a thorough history and physical examination before starting stimulant medications, with an emphasis on the identification of risk factors for sudden death, but does not routinely recommend electrocardiographic screening or cardiac subspecialist consultation unless indicated by history or physical examination findings. A checklist for identifying children who are potentially at risk of sudden death (independent of ADHD or medications used to treat it) is provided. Although recommendations are based on the best evidence currently available, the committee further agrees that more research on this subject is necessary to optimize the approach to this common clinical scenario.
File Format	HTM / HTML
ISSN	0828282X
e-ISSN	19167075
Journal	Canadian Journal of Cardiology
Issue Number	11
Volume Number	25
Language	English
Publisher	Elsevier
Publisher Date	2009-11-01
Publisher Place	Great Britain (UK)
Access Restriction	Open
Subject Keyword	Discipline Cardiology Attention Deficit Disorder With Hyperactivity Drug Therapy Cardiovascular Diseases Diagnosis Central Nervous System Stimulants Therapeutic Use Death, Sudden, Cardiac Prevention & Control Adolescent Canada Mortality Adverse Effects Child, Preschool Dose-response Relationship, Drug Drug Administration Schedule Electrocardiography Mass Screening Risk Assessment Sex Factors Sickness Impact Profile Practice Guideline
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry

Electrocardiogram before starting stimulant medications: to order or not?

Stimulant treatment of ADHD and risk of sudden death in children.

Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.

Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder.

Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Similar Documents

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry

Electrocardiogram before starting stimulant medications: to order or not?

Stimulant treatment of ADHD and risk of sudden death in children.

Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.

Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder.

Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.